References
- Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski R, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019; 381: 1535-46. doi: 10.1056/NEJMoa1910836
- Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 2019; 30: 582-8. doi: 10.1093/annonc/mdz011
- Robert C, Hwu W-J, Hamid O, Ribas A, Weber JS, Daud AI, et al. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma. Eur J Cancer 2021; 144: 182-91. doi: 10.1016/j.ejca.2020.11.010
- Hocevar M, Strojan P, Ocvirk J, Peric B, Blatnik O, Luzar B, et al. [Recommendation for the treatment of patients with melanoma]. [Slovenian]. Rebersek M, editor. [cited 2020 Oct 15]. Ljubljana: Institute of Oncology Ljubljana; 2019. Available at: https://www.onko-i.si/fileadmin/onko/datoteke/Strokovna_knjiznica/smernice/Priporocila_za_obravnavo_bolnikov_z_melanomom_2020.pdf
- Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U, on behalf of the ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 1884-901. doi: 10.1093/annonc/mdz411
- NCCN Clinical Practice Guidelines in Oncology, Cutaneous melanoma. Version 4.2020. [cited 2020 Oct 14]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
- Bisschop C, Wind TT, Blank CU, Koornstra RHT, Kapiteijn E, Van den Eertwegh AJM, et al. Association between pembrolizumab-related adverse events and treatment outcome in advanced melanoma: results from the Dutch Expanded Access Program. J Immunother 2019; 42: 208-14. doi: 10.1097/CJI.0000000000000271
- Suo AE, Chan Y, Cheung WY, Monzon JG, Smylie M, Walker JWT, et al. Pembrolizumab-induced immune related adverse events and survival outcomes in advanced melanoma. [abstract]. J Clin Oncol 2018; 36 (15 Suppl): e21577. doi: 10.1200/JCO.2018.36.15_suppl.e21577
- Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S, et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis. Cancer Treat Rev 2021; 92: 102134. doi: 10.1016/j.ctrv.2020.102134
- Nishijima TF, Shachar SS, Nyrop KA, Muss HB. Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist 2017; 22: 470-9. doi: 10.1634/theoncologist.2016-0419
- EMA. Annex I. Summary of product characteristics. Ipilimumab (Yervoy) product information. [cited 2020 Oct 13]. Available at: https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-infor-mation_en.pdf
- EMA. Annex I. Summary of product characteristics. Pembrolizumab (Keytruda) product information: [cited 2020 Oct 12]. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf
- EMA. Annex I. Summary of product characteristics. Nivolumab (Opdivo) product information: [cited 2020 Oct 11]. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_sl.pdf
- Hribernik N, Boc M, Ocvirk J, Knez-Arbeiter J, Mesti T, Ignjatovic M, et al. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab – real-world experience. Radiol Oncol 2020; 54: 119-27. doi: 10.2478/raon-2020-0003
- Bystryn JC. Serum antibodies in vitiligo patients. Clin Dermatol 1989; 7: 136-45; doi: 10.1016/0738-081x(89)90063-1
- Oyarbide-Valencia K, van den Boorn JG, Denman CJ, Li M, Carlson JM, Hernandez C, et al. Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev 2006; 5: 486-92. doi: 10.1016/j.autrev.2006.03.012
- Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 2016; 152: 45-51. doi: 10.1001/jamadermatol.2015.2707
- Dick J, Lang N, Slynko A, Kopp-Schneider A, Schulz C, Dimitrakopoulou-Strauss A, et al. Use of LDH and autoimmune side effects to predict response to ipilimumab treatment. Immunotherapy 2016, 8: 1033-44. doi: 10.2217/imt-2016-0083
- Olson D, Luke JJ, Poklepovic AS, Bajaj M, Higgs E, Carll TC, et al. Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial. [abstract]. J Clin Oncol 2020; 38 (Suppl 15): 10004. doi: 10.1200/JCO.2020.38.15_suppl.10004
- Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, et al. Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. J Clin Oncol 2019; 37: 52-60. doi: 10.1200/JCO.18.00204.
- Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 2018; 19: 672-81. doi: 10.1016/S1470-2045(18)30139-6
- Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 2018; 379: 722-30. doi: 10.1056/NEJMoa1805453